Literature DB >> 10455412

Overexpression of urokinase receptor in mammalian cells following administration of the in vitro transcribed encoding mRNA.

K Karikó1, A Kuo, E Barnathan.   

Abstract

The ability to overexpress physiologically important proteins in cultured mammalian cells after delivering the encoding mRNAs could have important applications for analyzing their in vivo functions. To explore the potential of this approach, urokinase-type plasminogen activator receptor (uPAR), a membrane protein extensively modified post-translationally, was selected. The uPAR-encoding mRNAs, containing different 5' and 3' untranslated regions (UTR) were tested in cultured human osteosarcoma (HOS) cells following a cationic lipid-mediated delivery. The most effective structure was the capped and polyadenylated transcript containing Xenopus beta-globin 5' and 3' UTRs. Delivering this mRNA to HOS cells resulted in a significant increase of uPAR expression in 89% of the cells, measured by flow cytometry. Using a radioligand binding assay, the increase in functional uPAR levels was found to be up eight- to 11-fold between 8 and 48 h and up three-fold at 72 h after delivery. A similar increase in uPAR levels was achievable in a number of mammalian cell lines. Surprisingly, poly(A)-tailed mRNA leading to a uPAR production highest in magnitude and duration did not demonstrate increased intracellular stability compared with other tested mRNAs. Thus, the exceptional translational performance is not likely the result of an increased mRNA half-life. These results demonstrate that, after delivery of selected mRNAs into mammalian cells, immediate and significant overexpression of a post-translationally modified protein is achievable.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10455412     DOI: 10.1038/sj.gt.3300930

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  23 in total

Review 1.  Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.

Authors:  S Guan; J Rosenecker
Journal:  Gene Ther       Date:  2017-01-17       Impact factor: 5.250

Review 2.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

Review 3.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

4.  Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells.

Authors:  T Bettinger; R C Carlisle; M L Read; M Ogris; L W Seymour
Journal:  Nucleic Acids Res       Date:  2001-09-15       Impact factor: 16.971

Review 5.  Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases.

Authors:  Zeljka Trepotec; Eva Lichtenegger; Christian Plank; Manish K Aneja; Carsten Rudolph
Journal:  Mol Ther       Date:  2018-12-22       Impact factor: 11.454

Review 6.  Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases.

Authors:  Itishri Sahu; A K M Ashiqul Haque; Brian Weidensee; Petra Weinmann; Michael S D Kormann
Journal:  Mol Ther       Date:  2019-03-06       Impact factor: 11.454

7.  Vaccine-delivered HIV envelope inhibits CD4(+) T-cell activation, a mechanism for poor HIV vaccine responses.

Authors:  Kathy Fernando; Haitao Hu; Houping Ni; James A Hoxie; Drew Weissman
Journal:  Blood       Date:  2006-12-07       Impact factor: 22.113

Review 8.  Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease.

Authors:  Yoav Hadas; Michael G Katz; Charles R Bridges; Lior Zangi
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-12-02

9.  Biomaterials for mRNA delivery.

Authors:  Mohammad Ariful Islam; Emma K G Reesor; Yingjie Xu; Harshal R Zope; Bruce R Zetter; Jinjun Shi
Journal:  Biomater Sci       Date:  2015-08-17       Impact factor: 6.843

Review 10.  Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety.

Authors:  Irena Vlatkovic
Journal:  Biomedicines       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.